- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Aventis Streamlines R&D
Pharmaceutical Executive
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share.
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share. Aventis will retain the other 42 percent. ProSkelia, based in Romainville, near Paris, France, special-izes in early-stage research into treatments for bone disease.
Aventis also intends to spin off its gene therapy unit, Gencell, but it has yet to find a partner that is prepared to meet its valuation. Attempts to reduce research cash burn follow Aventis' discontinuation of trials for two of the company's pipeline compounds. Development of the ACE/NEP (angiotensin con-verting enzyme/neutral endopeptidase) inhibitor M100,240 for the treatment of hypertension was stopped after a Phase II clinical trial yielded disappointing results. Aventis says it intends to examine the drug's possibilities in other therapeutic uses.
It has also terminated a co-development agreement with ViroPharma of Exton, Penn-sylvania, for the antiviral agent Picovir (pleconaril), intended to treat the common cold. FDA issued a non-approvable letter for it in May.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
